DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Bladder Cancer Therapeutics Market 2017-2021" report to their offering.
The global bladder cancer therapeutics market to grow at a CAGR of 4.77% during the period 2017-2021.
The report, Global Bladder Cancer Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
One trend in the market is advent of novel pipeline. The global bladder cancer therapeutics market is expected to grow due to the presence of novel therapies in the early stages of the pipeline. For instance, the adoptive cell therapy utilizes the immunotherapy approach for the treatment of bladder cancer.
According to the report, one driver in the market is growing prevalence rate leads to higher prescription value. Bladder cancer is the ninth-most type of cancer diagnosed worldwide, with the highest incidence rates demonstrated by males in Southern and Western Europe, North America, and in certain countries in Northern Africa or Western Asia. Bladder cancer ranked among 15 most common causes of deaths worldwide.
- Bristol-Myers Squibb
- Eli Lilly
- F. Hoffman-La Roche
Other prominent vendors
- Accord Healthcare
- Bedford Lab
Key Topics Covered:
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
PART 05: Key clinical trials
PART 06: Market landscape
PART 07: Market segmentation by therapy
PART 08: Geographical segmentation
PART 09: Decision framework
PART 10: Drivers and challenges
PART 11: Market trends
PART 12: Vendor landscape
PART 13: Key vendor analysis
PART 14: Appendix
For more information about this report visit http://www.researchandmarkets.com/research/3xp5xx/global_bladder